Inovio Pharmaceuticals has surged 24% in a week to $1.41, but its short sellers are not backing down — and the gap between those two signals makes this week's setup genuinely uncomfortable.
Short interest has climbed to 18.4% of the free float, up from roughly 12.9% a month ago — a 37% increase in four weeks. This is not a stock with residual bears; the bears are actively adding. The move is concentrated in the back half of April through early May, with shorts jumping from ~10 million shares to nearly 15 million in barely three weeks. FINRA-reported data through April 30 puts official short interest at 14.2 million shares, implying days-to-cover just under 10 — unusually high for a micro-cap biotech.
The borrow picture reinforces how tight things are getting. Availability has dropped to around 17%, meaning only about one share remains available in the lending pool for every six already borrowed. That is firmly in "very tight" territory. Cost to borrow has climbed to 3.9%, up roughly 19% over the week — still not punishing, but creeping higher alongside the rising short position. The ORTEX short score sits at 77.4, near the top of the universe on a percentile basis, and the utilization rank is in the 6th percentile. Both flag an extreme borrow profile. If the price move continues, the squeeze arithmetic gets uncomfortable for late shorts.
Options traders are not hedging. The put/call ratio has collapsed to 0.035 — near its 52-week low of 0.014 and almost 1.5 standard deviations below its 20-day average of 0.22. The message is unambiguous: call buying has overwhelmed puts almost entirely. That skew mirrors the price action this week but is also a warning — a PCR this depressed often reflects speculative demand rather than fundamental conviction, and it has reversed sharply before. Just two weeks ago the PCR was running above 0.29 consistently.
The Street offers cautious long-side support, though analyst data here is stale enough to warrant care. The most recent action on record is a Piper Sandler Overweight reiteration with a $6.00 target from November 2025. HC Wainwright holds a Neutral with a $3.00 target. With the stock trading at $1.41, even the more bearish target implies significant upside on paper — but the analyst community has been thin on fresh coverage. The mean price target of $5.96 implies analyst-implied return potential of over 300%, which reflects the speculative nature of the name more than any near-term catalyst consensus. The company carries an enterprise value of roughly $48 million and generates no revenue, operating in DNA medicine with pipeline assets including INO-3107 and INO-5401. The EPS surprise score ranks in just the 8th percentile, confirming a persistent miss track record.
Institutional ownership is concentrated but not especially active. FMR (Fidelity) holds 11.4% of shares, the largest single position. Vanguard added 600k shares in Q1. D.E. Shaw and ADAR1 Capital are each on record as having built new or substantially expanded positions as of December 2025. Insider activity is negligible in dollar terms — the largest recent transaction on record was the CEO selling roughly $24,000 of stock at $1.79 in late February, part of a round of award-linked sales across the C-suite. None of the activity signals directional conviction.
Inovio reports its next earnings event on May 20. The most recent historical print, on May 8, produced a 4.4% one-day move. The March print moved the stock just under 2% before fading. With options so aggressively call-heavy and short interest near a multi-month high, the May 20 release is the next moment where the divergence between these two positioning signals has to resolve.
See the live data behind this article on ORTEX.
Open INO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
